crystals

Article
2,3-Dihydroquinazolin-4(1H)-one as a New Class of
Anti-Leishmanial Agents: A Combined Experimental and
Computational Study
Muhammad Sarfraz 1,2,† , Chenxi Wang 1,† , Nargis Sultana 2 , Humna Ellahi 3 , Muhammad Fayyaz ur Rehman 2, * ,
Muhammad Jameel 2 , Shahzaib Akhter 2 , Fariha Kanwal 4 , Muhammad Ilyas Tariq 2, * and Song Xue 1, *
1 Department of Cardiovascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai 200240, China; [email protected] (M.S.); [email protected] (C.W.)
2 Institute of Chemistry, University of Sargodha, Sargodha 40100, Pakistan; [email protected] (N.S.);
[email protected] (M.J.); [email protected] (S.A.)
3 Department of Psychiatry, Lahore General Hospital, Lahore 54000, Pakistan; [email protected]
4 Med-X Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University,
Shanghai 201620, China; [email protected]
* Correspondence: [email protected] (M.F.u.R.); [email protected] (M.I.T.);
[email protected] (S.X.); Tel.: +92-300-4474407 (M.F.u.R.)
† These authors contributed equally to this work.

Abstract: Leishmaniasis is a neglected parasitic disease caused by various Leishmania species. The
discovery of new protozoa drugs makes it easier to treat the disease; but, conventional clinical
issues like drug resistance, cumulative toxicity, and target selectivity are also getting attention.



So, there is always a need for new therapeutics to treat Leishmaniasis. Here, we have reported 2,3-


dihydroquinazolin-4(1H)-one derivative as a new class of anti-leishmanial agents. Two derivatives, 3a
Citation: Sarfraz, M.; Wang, C.;
Sultana, N.; Ellahi, H.; Rehman,
(6,8-dinitro-2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-ones) and 3b (2-(4-chloro-3-nitro-phenyl)-
M.F.u.; Jameel, M.; Akhter, S.; 2-methyl-6,8-dinitro-2,3-dihydro-1H-quinazolin-4-one) were prepared that show promising in silico
Kanwal, F.; Tariq, M.I.; Xue, S. anti-leishmanial activities. Molecular docking was performed against the Leishmanial key proteins in-
2,3-Dihydroquinazolin-4(1H)-one as cluding Pyridoxal Kinase and Trypanothione Reductase. The stability of the ligand-protein complexes
a New Class of Anti-Leishmanial was further studied by 100 ns MD simulations and MM/PBSA calculations for both compounds. 3b
Agents: A Combined Experimental has been shown to be a better anti-leishmanial candidate. In vitro studies also agree with the in-silico
and Computational Study. Crystals results where IC50 for 3a and 3b was 1.61 and 0.05 µg/mL, respectively.
2022, 12, 44. https://doi.org/
10.3390/cryst12010044 Keywords: Leishmania; Quinazoline; anti-leishmanial agents; MD simulations
Academic Editors: Leonid Kustov
and Shujun Zhang

Received: 19 November 2021

1. Introduction
Accepted: 14 December 2021
Published: 29 December 2021
Leishmaniasis is caused by a protozoan parasite of the Leishmania genus that has
become a serious public health concern regarding diagnosis, prevention, and cure [1,2].
Publisher’s Note: MDPI stays neutral
Biting over 90 species of female sandfly vectors of the genera Lutzomyia and Phlebotomus
with regard to jurisdictional claims in
are known to transfer these parasites from one host by infecting the host while taking a
published maps and institutional affil-
blood meal. Leishmania disease has been classified as a neglected tropical disease associated
iations.
with population displacement, malnutrition, weak immune system, and poor housing.
It is estimated that around 1 million new cases of the contagious disease occur every
year [3,4]. The number increases due to the association and co-infection with the human
Copyright: © 2021 by the authors.
immunodeficiency virus (HIV) and Leishmania. The situation aggravates due to the non-
Licensee MDPI, Basel, Switzerland. availability of effective therapy or treatment for such patients [5,6].
This article is an open access article Leishmaniasis exists in many forms that depend on species of parasite infecting the
distributed under the terms and host. Clinically, the disease exists in three different forms, namely mucocutaneous (skin,
conditions of the Creative Commons nose, and mouth), cutaneous (skin ulcers), and visceral leishmaniasis (starting from skin
Attribution (CC BY) license (https:// ulcers causing fever, enlargement of liver/spleen, and low red blood cells) [7]. The later
creativecommons.org/licenses/by/ form of Leishmaniasis is chronic, mainly caused by L. donovani, L. infantum, and L. cha-
4.0/). gasi, resulting in debilitating infection of the reticuloendothelial system and is fatal if left

Crystals 2022, 12, 44. https://doi.org/10.3390/cryst12010044 https://www.mdpi.com/journal/crystals

Crystals 2022, 12, 44 2 of 17

untreated [8,9]. Currently, there are no approved vaccines or prophylactic drugs against
any form of leishmaniasis [10]. Thus, conventional chemotherapy is used to control and
manage disease by using pentavalent antimonials like organic complexes with SbV including
meglumine antimoniate (Glucantime® ) and sodium stibogluconate (Pentostam® ) through
multiple parenteral administrations. Still, there are reports of considerable toxicity and
reduced activity due to induced resistance [11,12].
Other second-line therapeutic agents include amphotericin B and its lipid formula-
tions, Miltefosine, pentamidine, and a phosphocholine analog, but these drugs have also
developed resistance, are too toxic, or too expensive for common patients in the developing
countries [13,14]. Apropos, the discovery of economical and efficient chemotherapy for
leishmaniasis is still awaited, so the development of new efficient, safe and cheap therapeu-
tic alternatives is urgently needed. Several researchers have reported the anti-leishmanial
activity of versatile synthetic compounds [15–21] and the potential of alternative entities
and new strategies [22,23].
Since the last couple of decades, medicinal scientists have switched their attention
to using different enzyme inhibitors to control and treat various psychological disorders
and health implications resulting from malfunction or over-activity of enzymes. Various
enzyme inhibitors have been designed and reported to control different diseases and
disorders [24–30].
Quinazolines show promising antileishmanial, antimalarial, antibacterial, antidiabetic,
antifungal, anthelmintic, cardiotonic, anticonvulsant, anti-inflammatory, antiviral, analgesic,
antidiuretic, cytotoxicity, antitumor, and many other biological activities [31–42]. Several
researchers have synthesized and documented the potential of quinazoline derivatives as
anti-leishmanial agents [16,43–51]. There are more than 150 naturally occurring alkaloids
with the Quinazoline scaffold, including echinozolinone, glucosamine, rutaecarpine, and
deoxyvascinone have been reported from animals, microorganisms, and plants kingdoms
are structural subunits of this scaffold [52].
Quinazoline scaffolds also display immense importance for designing and developing
some clinically proven and commercially available drugs such as Gefitinib (used against lung
cell cancer), Proquazone (a non-steroidal anti-inflammatory drug), Doxazosin (an antihyper-
tensive agent), Prazosin (used to treat high blood pressure), Erlotinib (useful for pancreatic
cancer, small cell lung cancer and several other types of cancer), Quinethazone (used to treat
hypertension), Febrifugine (used as antimalarial), Afloqualone (used as sedative and muscle
Crystals 2021, 11, x FOR PEER REVIEW
relaxant), Fenquizone (used as antidiuretic), and many other pharmacological active3drug of 18
candidates (Figure 1) [53,54].

Figure1.1.Quinazoline-based
Figure Quinazoline-baseddrugs.
drugs.

In a previous
2. Materials study, we have reported the synthesis and cholinesterase inhibitory
and Methods
activity of several 2,3-dihydroquinazolin-4(1H)-ones derivatives
Analytical-grade chemicals, reagents, and solvents used for[26]. Keeping in
quinazoline view the
derivatives
versatile nature of quinazoline moiety and pursuing the strategy of developing
preparation were of analytical grade as received from suppliers. Anthranilamide, potent
ethyl
methyl ketone, diethyl ketone, methyl-(4-chloro phenyl) ketone, triethyl amine (Et3N), hy-
drochloric acid (HCl), nitric acid (HNO3), and DCM was purchased from Merck Millipore
and Sigma-Aldrich, UK. Melting points were measured by using an SMP30 Stuart Scien-
tific melting point apparatus. The 1H and 13C NMR spectra were recorded using Bruker
Crystals 2022, 12, 44 3 of 17

anti-leishmanial agents, we have designed our research project to evaluate the biological
potential of a relatively new class of di-substituted 2,3-dihydroquinazolin-4(1H)-one moiety
through molecular docking and in vitro assay study.

2. Materials and Methods

Analytical-grade chemicals, reagents, and solvents used for quinazoline derivatives
preparation were of analytical grade as received from suppliers. Anthranilamide, ethyl
methyl ketone, diethyl ketone, methyl-(4-chloro phenyl) ketone, triethyl amine (Et3 N),
hydrochloric acid (HCl), nitric acid (HNO3 ), and DCM was purchased from Merck Millipore
and Sigma-Aldrich, UK. Melting points were measured by using an SMP30 Stuart Scientific
melting point apparatus. The 1 H and 13 C NMR spectra were recorded using Bruker DRX
400 MHz NMR spectrometers using CDCl3 as solvent. All chemical shifts are reported with
reference to SiMe4 and corresponding residual 1 H and 13 C solvent peaks. Bruker Smart
APEX II diffractometer was used for collecting X-ray diffraction data of the crystals. Data
reduction was carried out using the SAINT program, and structure solution and refinements
were performed with the SHELXL-2013 program package.

2.1. General Procedure for the Synthesis of 6,8-dinitro-2,2-disubstituted-2,3-dihydroquinazolin-

4(1H)-ones (3a and 3b)
The ligands 3a and 3b were synthesized and characterized as stated previously [55]
wherein a solvent-free condensation of anthranilamide1 and ketone 2 was carried out
by adding a few drops of conc. HNO3 and 2,3-dihydroquinazolin-4(1H)-one derivatives
were prepared by heating the reaction mixture under reflux conditions for 30 min. The
intermediate compound was concentrated on a rotary evaporator and cooled down. Further,
this compound (100 mM) was dissolved in conc. H2 SO4 (10 mL) and conc. HNO3 (0.5 mL)
was added dropwise while stirring in an ice bath. Stirring was continued for 6 h, and the
reaction mixture was poured on crushed ice. Precipitates so formed were filtered, washed
with water, and dried in an oven. Recrystallization with ethanol afforded yellowish crystals
of 6,8-dinitro-2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-one which was characterized
by X-ray crystallographic and NMR techniques.

2.2. Synthesis of 6,8-dinitro-2,2-diethyl-2,3-dihydroquinazolin-4(1H)-one (3a)

As stated in [55], synthesis of compound 3a was achieved from reaction of 1 (13.6 g,
100 mmol) and diethyl ketone (21.5 mL, 200 mmol) by adopting general procedure as yellow
crystalline solid. (98.5% yield); m.p. 200–202 ◦ C; CCDC No. 1568517; 1 H NMR (400 MHz,
CDCl3 , 25 ◦ C): δ = 9.21 (d, 3 J = 8 Hz, 1H, ArH), 9.02 (d, 3 J = 8 Hz, 1H, ArH), 8.52 (s, 1H, NH),
6.67 (s, 1H, NH), 1.95–1.88 (m, 4H, 2 × CH2 ), 1.05 (t, 3 J = 7 Hz, 6H, 2 × CH3 ) ppm. 13 C NMR
(100 MHz, CDCl3 , 25 ◦ C), δ = 165.4, 144.2, 138.6, 134.5, 129.2, 123.1, 118.9, 66.3, 34.9, 6.4.

2.3. Synthesis of 2-(4-chloro-3-nitro-phenyl)-2-methyl-6,8-dinitro-2,3-dihydro-1H-

quinazolin-4-one (3b)
As stated in [55], 3b was prepared from a mixture of 1 (6.8 g, 50 mmol) and 4-chloro
acetophenone (13.0 mL, 100 mmol) by utilizing general synthesis procedure as yellow
crystalline solid. (95.8% yield); m.p. 200–202 ◦ C; CCDC 1508840; 1 H NMR (400 MHz,
CDCl3 , 25 ◦ C): δ = 9.21 (d, 3 J = 8 Hz, 1H, ArH), 9.07 (d, 3 J = 8 Hz, 1H, ArH), 8.36 (s, 1H,
NH), 8.14 (s, 1H, ArH), 7.63 (d, 3 J = 8 Hz, 1H, ArH), 7.57 (d, 3 J = 8 Hz, 1H, ArH), 6.45 (s,
1H, NH), 2.12 (s, 3H, CH3 ) ppm. 13 C NMR (100 MHz, CDCl3 , 25 ◦ C), δ = 168.2, 149.1, 143.5,
141.6, 138.4, 134.5, 133.6, 129.8, 129.2, 127.1, 124.6, 123.0, 119.6, 66.8, 30.4.

2.4. X-rays Crystallographic Study

Suitable crystals of the synthesized compounds were obtained by slowly evaporating a
solution of individual compounds in ethyl acetate/DCM/methanol (2:1:1). Bruker KAPPA
Apex II diffractometer having graphite-monochromatized Mo Ka radiation, λMo = 0.710 73 Å
at 100 K, was used to analyze crystals. Data reduction and structure refinement were
achieved using SAINT and SHELXL-2013 program packages. Material for publication was
Crystals 2022, 12, 44 4 of 17

prepared by using PLATON software [56,57]. Finalized crystal structure data was deposited
with Cambridge Crystallographic Data Centre (CCDC).

2.5. Anti-Leishmanial Activity

The 3a and 3b compounds were screened for anti-leishmanial activity in an in vitro assay,
where Amphotericin B deoxycholate and Miltefosine were used as the reference drugs [58].
In vitro inhibition of Leishmania growth was assessed using a 96-well growth plate assay
by modifying s previous method [58]. The promastigotes of L. amazonensis (1 × 106 cells)
were cultivated with various 3a and 3b concentrations for 48 h at 24 ◦ C. Cell viability was
observed by MTT assay [58]. The IC50 was determined using sigmoidal regression of the
concentration-response curves, and results were obtained in triplicates.

2.6. Molecular Docking and Molecular Dynamic Simulations

Molecular docking was performed to map the ligand interactions with Leishmanial
key protein involved in parasite viability. Protein structures for Pyridoxal Kinase and Try-
panothione Reductase from Leishmania sp. were obtained from Protein Data Bank (PDB) as
PDB IDs 6K92 and 6T98, respectively. The 3a and 3b ligands were optimized using the MM4
and screened against the proteins using a modified AutoDock-LGA module while applying
AMBER03-FF in YASARA Structure version 20.7.4 (available at Dr. Fayyaz’s Computational
Biology Lab) [59] as described earlier [60,61]. Binding energies were tabulated along with
dissociation constants, and LigPlus [62] was used to find ligand-protein interactions. Molec-
ular Dynamics (MD) were performed using AMBER14 as a force field in a 20 Å water-filled
space around the protein-ligand complexes obtained from molecular docking. The same
condition was used as described earlier [61,63,64] and 100 ns MD simulations were obtained.
Prism GraphPad ver 7.0 [65] was used to analyze the data. MMPBSA calculations were
employed by the binding energy module in YASARA using the following equation.

Binding Energy = EpotRecept + EsolvRecept + EpotLigand + EsolvLigand − EpotComplex − EsolvComplex

2.7. Determination of In Silico Pharmacokinetic Properties

The 3a and 3b ligands were screened for their pharmacokinetic potential and drug-
likeness using the SwissADME server (http://www.swissadme.ch/, accessed on 20 Septem-
ber 2021).
Crystals 2021, 11, x FOR PEER REVIEW 5 of 18

3. Results and Discussions

Condensation
3. Results of anthranilamide with ketone was achieved under Lewis acid catalysis
and Discussions
to produce intermediate quinazoline
Condensation of anthranilamide moiety,
with ketone waswhich was
achieved further
under Lewistreated with a nitrating mix-
acid cataly-
ture. Resultantly,
sis to produce compounds
intermediate (3amoiety,
quinazoline and 3b) were
which wassynthesized
further treatedby reacting
with the unsubstituted
a nitrating
mixture. Resultantly,
phenyl compounds (3a and 3b) were synthesized
ring of 2,3-dihydroquinazolin-4(1H)-one coreby reacting
with conc.theHNO
unsubsti-
3 in the presence of
tuted
H SOphenyl ring of
(Figure 2).2,3-dihydroquinazolin-4(1H)-one core with conc. HNO3 in the pres-
2 4
ence of H2SO4 (Figure 2).
-
O O O
+
H N H
N O N
O

H3C N N
O CH3 CH3
+
H CH3 - N H CH3
CH3 O O
NH2
Lewis acid Catalyst Conc. H2SO4 + HNO3
+ 3a
NH2 reflux 30 min
O
Stirr 6 Hrs, ice bath
O -
O O
H3C H +
N N H
O N
Cl CH3
N CH3
N
H +
- N H
O O

Cl - +
O N Cl
O
1 2 3b

Figure 2. Synthesis of 6,8-dinitro-2,3-dihydroquinazolin-4(1H)-ones.

Figure 2. Synthesis of 6,8-dinitro-2,3-dihydroquinazolin-4(1H)-ones.
3.1. NMR and XRD Study
1H NMR spectra of 6,8-dinitro-2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-ones

were elucidated with respect to corresponding chemical shift values, proton signals/peaks
in aromatic or aliphatic regions, and their coupling constants. In 1H NMR spectra, two
highly deshielded proton signals appeared in the range of 9.21–9.02 ppm (d, J = 8 Hz) due
Crystals 2022, 12, 44 5 of 17

3.1. NMR and XRD Study

1H NMR spectra of 6,8-dinitro-2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-ones
were elucidated with respect to corresponding chemical shift values, proton signals/peaks
in aromatic or aliphatic regions, and their coupling constants. In 1 H NMR spectra, two
highly deshielded proton signals appeared in the range of 9.21–9.02 ppm (d, J = 8 Hz) due to
aromatic protons of the pyrimidine phenyl ring. Two doublets (Jortho = 8 Hz) were assigned
to protons of phenyl ring attached to C-2 of compound 3b. Two broad singlets ranging from
6.67–6.45 ppm and 8.52–8.36 ppm were interpreted for the –NH protons at position-1 and 3
of the quinazoline ring. 1 H-NMR signals due to other protons of methyl and ethyl groups
Crystals 2021, 11, x FOR PEER REVIEW
were assigned at different chemical shift values [26]. 6 of 18

Structures of the synthesized compounds were confirmed by performing single-crystal

Crystals 2021, 11, x FOR PEER REVIEW X-ray diffraction (XRD) analysis by using suitable crystals of individual compounds
6 of 18 grown
in ethyl acetate. Ortep diagrams of compounds 3a and 3b are shown in Figures 3 and 4,
whereas crystal data is presented in Tables 1 and 2, respectively.

Figure 3. Ortep diagram of compound 3a (CCDC No. 1568517).

Figure 3. Ortep diagram of compound 3a (CCDC No. 1568517).

Figure 3. Ortep diagram of compound 3a (CCDC No. 1568517).

Figure Ortepdiagram
4. Ortep
Figure 4. diagramofof compound
compound 3b (CCDC
3b (CCDC No. 1508840).
No 1508840).

Figure 4.H-bonding presents

Ortep diagram in the 3a,
of compound 3b and 3b No
(CCDC has1508840).
been shown by the crystal (Figure 5). In the
case of 3b, the intramolecular hydrogen bonding was present between oxygen in the phe-
nyl ring (position
H-bonding 8) and
presents H-N1.
in the The 3b
3a, and intermolecular H-bonding
has been shown is also(Figure
by the crystal observed between
5). In the
the
case ofoxygen
3b, the of -C=O and H-N3
intramolecular (Figurebonding
hydrogen 5). was present between oxygen in the phe-
nyl ring (position 8) and H-N1. The intermolecular H-bonding is also observed between
Crystals 2022, 12, 44 6 of 17

Table 1. Crystal structure data of the compound 6,8-dinitro-2,2-diethyl-2,3-dihydroquinazolin-4(1H)-

one (3a).

COMPOUND 6,8-DINITRO-2,2-DIETHYL-2,3-DIHYDROQUINAZOLIN-4(1H)-ONE
Chemical Formula C12 H14 N4 O5
M (g mol−1 ) 294.27
Temperature (K) 296(2)
Crystal system triclinic
Space group P −1 Cell volume 668.21(13)
A (Å) 7.2979(9) α 74.633(7)
B (Å) 9.3899(10) β 82.799(7)
C (Å) 10.2950(11) γ 80.358(7)
C1 0.2542(3) 0.1917(3) 0.1182(2)
C2 0.2105(3) 0.2055(3) −0.0153(2)
C3 0.2138(3) 0.0835(3) −0.0662(2)
H3 0.1823 0.0961 −0.1537
C4 0.2638(3) −0.0568(3) 0.0133(2)
C5 0.3167(3) −0.0776(3) 0.1418(2)
H5 0.3553 −0.1732 0.1930
C6 0.3121(3) 0.0430(3) 0.1936(2)
C7 0.3904(4) 0.0215(3) 0.3242(2)
C8 0.2366(3) 0.2765(3) 0.3250(2)
C9 0.0347(4) 0.2546(3) 0.3813(2)
H9A −0.0464 0.3468 0.3478
H9B −0.0019 0.1785 0.3459
C10 0.0027(5) 0.2103(4) 0.5336(3)
H10A 0.0830 0.1196 0.5685
H10B −0.1250 0.1952 0.5593
H10C 0.0297 0.2880 0.5699
C11 0.2977(4) 0.4066(3) 0.3615(3)
H11A 0.2146 0.4964 0.3243
H11B 0.2831 0.3899 0.4591
C12 0.4944(5) 0.4334(4) 0.3133(4)
H12A 0.5788 0.3464 0.3512
H12B 0.5204 0.5171 0.3413
H12C 0.5100 0.4538 0.2164
N1 0.2466(3) 0.3024(2) 0.17796(18)
H1 0.2475 0.3919 0.1286
N2 0.3645(3) 0.1397(2) 0.37514(19)
H2 0.4267 0.1361 0.4419
N3 0.1546(4) 0.3500(3) −0.1038(2)
N4 0.2658(4) −0.1854(3) −0.0407(3)
O1 0.4806(3) −0.09969(19) 0.37765(16)
O2 0.1690(3) 0.4622(2) −0.07018(19)
O3 0.0948(5) 0.3551(3) −0.2099(2)
O4 0.2167(4) −0.1651(3) −0.1536(2)
O5 0.3161(5) −0.3090(3) 0.0304(2)
Crystals 2022, 12, 44 7 of 17

Table 2. Crystal structure data of the compound (2-(4-chloro-3-nitro-phenyl)-2-methyl-6,8-dinitro-2,3-

dihydro-1H-quinazolin-4-one (3b).

COMPOUND (2-(4-CHLORO-3-NITRO-PHENYL)-2-METHYL-6,8-DINITRO-2,3-DIHYDRO-1H-QUINAZOLIN-4-ONE
Chemical Formula C15 H10 N5 ClO7
M (g mol− 1 ) 407.5
Temperature (K) 372(2)
Crystal system triclinic
Space group P −1 Cell volume 841.094
A (Å) 6.8643(8) α 75.424(6)
B (Å) 9.2549(9) β 87.586(7)
C (Å) 13.7144(15) γ 86.231(7)
C1 0.6656(7) 0.1751(5) 0.8254(4)
C2 0.6775(7) 0.0369(5) 0.7961(4)
C3 0.5281(8) −0.0597(5) 0.8182(4)
H3 0.5382 -0.1484 0.7977
C4 0.3649(8) −0.0247(5) 0.8705(4)
C5 0.3486(7) 0.1037(5) 0.9045(4)
H5 0.2388 0.1241 0.9420
C6 0.4959(7) 0.2013(5) 0.8826(4)
C7 0.4912(8) 0.3295(5) 0.9310(4)
C8 0.7650(8) 0.4278(5) 0.8170(4)
C9 0.9567(9) 0.4859(7) 0.8365(6)
H9A 0.9337 0.5838 0.8481
H9B 1.0433 0.4914 0.7790
H9C 1.0148 0.4195 0.8947
C10 0.6525(17) 0.5296(12) 0.7192(6)
C11 0.4757(18) 0.6030(12) 0.7359(5)
H11 0.4210 0.5869 0.8006
C12 0.3807(14) 0.7005(10) 0.6557(7)
H12 0.2624 0.7496 0.6668
C13 0.4624(15) 0.7246(9) 0.5589(5)
C14 0.6392(16) 0.6512(10) 0.5422(5)
C15 0.7342(14) 0.5537(11) 0.6224(7)
H15 0.8525 0.5046 0.6113
CL1 0.3474(18) 0.8578(13) 0.4625(7)
N1 0.6380(6) 0.4198(4) 0.9038(3)
H1 0.6583 0.4785 0.9415
N2 0.8019(7) 0.2756(4) 0.8038(3)
H2 0.9147 0.2505 0.7814
N3 0.8464(7) −0.0089(5) 0.7414(4)
N4 0.2091(8) −0.1292(5) 0.8942(4)
O1 0.9864(6) 0.0713(4) 0.7251(3)
O2 0.8450(6) −0.1227(5) 0.7148(4)
O3 0.2263(6) −0.2401(5) 0.8615(4)
O4 0.0718(7) −0.1034(5) 0.9463(4)
O5 0.3663(6) 0.3415(4) 0.9956(3)
O6 0.914(6) 0.6698(14) 0.4572(12)
O7 0.638(5) 0.712(3) 0.3774(13)
N5 0.703(5) 0.680(4) 0.448(3)

H-bonding presents in the 3a, and 3b has been shown by the crystal (Figure 5). In the
case of 3b, the intramolecular hydrogen bonding was present between oxygen in the phenyl
ring (position 8) and H-N1. The intermolecular H-bonding is also observed between the
oxygen of –C=O and H-N3 (Figure 5).
 Crystals 2021, 11, x FOR PEER REVIEW 7 of 18

Crystals 2022, 12, 44 8 of 17

3a

3b
Figure5.5.Hydrogen
Figure Hydrogenbonding
bondingin
in3a
3aand
and3b
3b(colored
(coloredlines
linesshow
showH-bonding).
H-bonding).

3.2. Docking
Table Studies,
1. Crystal MMPBSA
structure data of Calculations
the compound and MD Simaultions
6,8-dinitro-2,2-diethyl-2,3-dihydroquinazolin-
4(1H)-one
Both (3a).
ligands 3a and 3b were found to interact with Pyridoxal Kinase (PDK) and
Trypanothione Reductase (TPR) from Leishmania sp. PDK is involved in phosphorylation
6,8-DINITRO-2,2-DIETHYL-2,3-DIHYDROQUINAZOLIN-4(1H)-
Compound
of B6 vitamers into pyridoxal-5-phosphate (PLP) [66]. ONE PDK is an interesting target for
anti-leishmanial activity
Chemical Formula as it is involved in drug resistance
C12H14N especially
4O5
Miltefosine [67].
3a interacts
M (g molwith
−1) Pyridoxal Kinase with a binding 294.27 energy of −9.84 kcal/mol and a
dissociation constant
Temperature (k) of 60.90 nM, while 1b interacts with Pyridoxal Kinase with a binding
296(2)
of −8.07
energy Crystal kcal/mol
system and dissociation constant 1.21 µM (Table 3).
triclinic
Space group P −1 Cell volume 668.21(13)
Table 3. Docking
A(Å)of the 3a and 3b against novel targets of Leishmania
7.2979(9) α proteins. 74.633(7)
B (Å) 9.3899(10) β 82.799(7)
C (Å) Docking Scores
10.2950(11) γ 80.358(7)
Ligands Leishmanial Targets PDBC1IDs Binding Energy0.2542(3)
(kcal/mol) 0.1917(3)
Dissociation Constant 0.1182(2)
MM/PBSA
Pyridoxal Kinase C2
6K92 0.2105(3)
−9.84 0.2055(3)
60.90 nM −0.0153(2)
−94 KJ/mol
3a C3 0.2138(3) 0.0835(3) −0.0662(2)
Trypanothione reductase 6T98 −11.35 4.78 nM − 113 KJ/mol
H3 0.1823 0.0961 −0.1537
Pyridoxal Kinase 6K92 −8.07 1.21 µM −32 KJ/mol
3b C4 0.2638(3) −0.0568(3) 0.0133(2)
Trypanothione reductase 6T98 −8.75 380 nM −61 KJ/mol
C5 0.3167(3) −0.0776(3) 0.1418(2)
H5 0.3553 −0.1732 0.1930
The bestC6 ligand includes Val190.0430(3)
binding site for the 3a0.3121(3) , Asp119 , Val121 , 124 , Tyr129 ,
0.1936(2)
Asp
Asn151 , Tyr152 , Glu154 , Lys187 , Ser188 , Leu198 , Val219 , Tyr226 , Thr227 , Gly228 , Thr229 , Gly230 ,
Asp231 , Phe233 , Met254 , Leu257 , and Gln258 . Here, the binding site residues contain 228 GTGD231
 Crystals 2022, 12, 44 9 of 17
21, 11, x FOR PEER REVIEW 10 of 18

motif and Gln258, which are conserved key residues in PDK [68]. For 3b, the binding site
overlapped the 3a active site and consisted of amino acids including, Asn151 , Lys187 , Ser188 ,
In the case
Leuof1983b, the
, Val 219calculated
, Pro220 , Tyrpotential
221 , His222 energy
, Tyr226 , is
Thrcomparatively
229 , Gly230 , Pheequal to254the
233 , Met native
, Leu257 , Gln258 ,
receptor and and
3a. RMSD-Cα
261 was not found to fluctuate as
228 in the
231case
Ile (Figure 6). The 3b ligand contains GTGD motif residues and conserved of the 3a-receptor
complex (Figure 6). and
Gln258 RMSD and
Ile261 RMSFSer
residues. were found changing
188, another conservedin the regions
residue presentofin50–59, 149–site of
the binding
169, 225–245, and 254–260 (Figure 8). The region consisting of 225–231 consists ofenergy
both ligands, is involved in the α or β phosphate binding in ATP [68]. MM/PBSA
calculations
228GTGD231 motif, using YASARA
and fluctuation Structure
in this part ofshow a freeshow
receptor of −94interactions
energyligand and −113 KJ/mol with for 3a
and 3b complex
these particular amino acids. with PDK (Table 3).

3a
-9.84 kcal/mol
60.90 nM

3b
-8.07 kcal/mol
1.21 µM

Figure 6. The 3aFigure

and 3b 6. binding to the
The 3a and proteinto
3b binding structure of Pyridoxal
the protein Kinase
structure of (PDB
Pyridoxal ID 6K92).
Kinase (PDBThe top The
ID 6K92).
panels show 3atopforms H-bonds with Asn 151 (2.69 and 3.44Å) and Asp231 (3.44 Å). The 3b forms H-
panels show 3a forms H-bonds with Asn151 (2.69 and 3.44 Å) and Asp231 (3.44 Å). The 3b forms
bonds with LysH-bonds
187 (3.01 Å), His222 (2.66 and 2.73 Å), and Thr22 (2.87 Å). (Hydrogen bonding is shown
with Lys187 (3.01 Å), His222 (2.66 and 2.73 Å), and Thr22 (2.87 Å). (Hydrogen bonding is
by light green color dotted lines).
shown by light green color dotted lines).
-500000
In a previous study, a total of 5587 ligands were screened against PDK, and more
than 1000 compounds were foundNative to have binding properties to the enzyme [69]. A ligand,
1a3a
DNDI1103666, was ranked highest 1b3b in enzyme binding. This ligand shares the enzyme
binding site with 3a and 3b ligands in this study. The binding site overlapping residues
Potential Energy (kJ/mol)

-600000

include the Val19 , Asp124 , Asn151 , Tyr152 , Lys187 , Ser188 , His222 , and Tyr226 [69].
The MD simulations in the case of 3a (active site binding) show that equilibrium was
-700000
achieved after 60 ns (Figure 7). Compared with the native receptor, the 3a protein complex
shows a lot of fluctuations while calculating RMSD-Cα. In the case of 3a, fluctuations in
the RMSD-Cα are observed throughout the protein while these were higher in the region of
amino acids 9–54 (Figure 7), while four different regions show fluctuations in the RMSD and
-800000
RMSF values. These fluctuations also confirm ligand interactions with the protein receptor.
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100

These regions include

Time (ns)
the amino acids 14–34, 44–54, 95–115, 225–232, and 255–282 (Figure 8).
2.5
This confirms the ligand interactions with the receptor.

2.0
RMSD Cα (A°)

1.5

1.0

0.5
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100

Time (ns)
 Figure 6. The 3a and 3b binding to the protein structure of Pyridoxal Kinase (PDB ID 6K92). The top
panels show 3a forms H-bonds with Asn151 (2.69 and 3.44Å) and Asp231 (3.44 Å). The 3b forms H-
Crystals 2022, 12, 44 10 of 17
bonds with Lys187 (3.01 Å), His222 (2.66 and 2.73 Å), and Thr22 (2.87 Å). (Hydrogen bonding is shown
by light green color dotted lines).

-500000

Native
1a3a
1b3b

Potential Energy (kJ/mol)

-600000

-700000

-800000
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100
Time (ns)

2.5

2.0
RMSD Cα (A°)

1.5

1.0

0.5
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100
Time (ns)

Figure 7.
Figure
Crystals 2021, 11, x FOR PEER REVIEW
7. The 100 ns MD
MD simulations
simulations for 3a and
and 3b
3b show
show potential
potential energy
energy in
in the
the top
top panel,
panel, while
11while
of 18
RMSD-Cα isisshown
RMSD-Cα shownininthe
thebottom
bottompanel.
panel.3a3a shows
shows comparatively
comparatively more
more significant
significant fluctuations
fluctuations in
in the
the complex form during 20–50 ns of simulation.
complex form during 20–50 ns of simulation.
8

6
ΔRMSF (Å)

0
14
19

As 9
As 4
n39

Tyr 4
Gly 9

Th 9
r64

Ph 9
Ala 4

94
Glu 99

As 14
As 19
2
p3

r4
4

u5

u6
e7
24

54

79
84
g89

Gln 04
109

Tyr 24
Val 9
Ar 34

Th 44
Glu 49
Se 4
Lys 59
Ala 64

Gln 74
Val 9
Ph 84
As 89
Ar 4

Gly 04

Pr 15

Pr 40

Gly 50

0
265

Val 7
282
Pr 87

Pr 7
Ser9

15

u26
12

g139

169

17

p19

Cys 9

Tyr 0

Ar 0
Gly 5
Ala 0
Ph 5
o245

Le 5

r27

Le 2
u29
o302
Asp4

p1
Ala

Gly

p1

1
r1

r1
1

n1

1
e1

e2

p2
Gln

Gln

g19

21

o22
g22
23
23

25

o29
1
Val
Val

Val

Ala
Se

Ar

Ile
His

Val
Le

Le

Se
As

As

8 Amino acids

6
ΔRMSD (Å)

0
Va 14
A 19

A 29
A 34
Se 39
Ty 44
G 49

Th 59
Le 64
Ph 69
Al 74

V 94
G al 99

A 1 14
A 119
G 24

Le 54

a79
A 84
G 89

G 104
A 109

Ty 124
Va 129
A l 134

Th 44
G 149
Se 154
Ly 159
A 164

G 174
Va 179
Ph 184
A e189
A 194

G 204

Pr 215

Pr 240

G 250

Ile 60
Se 265
Va 277
A 282
Pr 287

Pr 297
Va 9

H 139

A 169

C 199

Ty 210

A 220
G 225
A 30
Ph 35

Va 245

Le 55

Le 292

2
p4
r

o30
la

ly

ly
rg

is1

u2
ln
sp
sn

ln
Se
l
l

ly2
la2

ly2
As

sp
la

rg

rg

ly
lu
ln

sp

r
lu
r

la
sn
ln

sp

o
rg

e
o

sp
o
u
s

ys

l
r

r
G

Amino acids

where potential
Figure 8. The 100 ns MD simulations for 3a and 3b, where potential energy has been shown in the
top panel, while RMSD-Cα is shown in the bottom panel. 3a shows comparatively more significant
fluctuations in
fluctuations in the
the complex
complex form
form during
during 20–50
20–50 ns
ns of
of simulation.
simulation.

Trypanothione Reductase (TPR) maintains the redox balance and converts trypano-
thione disulfide to the reduced trypanothione dithiol. Anti-leishmanial agents like artonin
B have shown strong enzyme inhibition in the in silico studies [70]. The 3a has shown very
strong interactions with TPR showing binding energy of −11.35 kcal/mol and dissociation
 Crystals 2022, 12, 44 11 of 17

In the case of 3b, the calculated potential energy is comparatively equal to the native
receptor and 3a. RMSD-Cα was not found to fluctuate as in the case of the 3a-receptor
complex (Figure 6). RMSD and RMSF were found changing in the regions of 50–59, 149–169,
225–245, and 254–260 (Figure 8). The region consisting of 225–231 consists of 228 GTGD231
motif, and fluctuation in this part of receptor show ligand interactions with these particular
amino acids.
Trypanothione Reductase (TPR) maintains the redox balance and converts trypanoth-
ione disulfide to the reduced trypanothione dithiol. Anti-leishmanial agents like artonin B
have shown strong enzyme inhibition in the in silico studies [70]. The 3a has shown very
strong interactions with TPR showing binding energy of −11.35 kcal/mol and dissociation
constant of 4.78 nM (Table 2). The binding site includes the amino acids, Leu10, Gly11 , Val34 ,
Asp35 , Val36 , Gly125 , Phe126 , Gly127 , Glu141 , Thr160 , Trp163 , Pro289 , Arg290 , Ser291 , Gln292 ,
Ala293 , and Leu294 (Figure 8).
Ligand 3b also shows TPR binding with comparatively less affinity than 3a. The
binding energy for 3b was −8.75 kcal/mol, and the dissociation constant was calculated
as 383.72 nM (Table 3). The 3b ligand binding site occupies a different binding site than
3a consisting of Gly11 , Gly13 , Ser14 , Gly15 , Gly16 , Ala46 , Gly49 , Gly50 , Thr51 , Cys52 , Val53 ,
Ala159 , Thr160 , Gly161 , Ser162 , Arg287 , Arg290 , Gly326 , Asp327 , Leu334 , Thr335 , and Ala338
(Figure 9). Here, Cys52 is a catalytic residue, while the FAD-binding domain consists
of 1–160 residues, the NADPH-binding domain compasses 161 to 288 amino acids [71].
Aryl-substituted imidazole has been found to bind to the same binding site in TPR as 3a
and 3b, where one ligand showed binding energy of −11.30 kcal/mol and dissociation of
Crystals 2021, 11, x FOR PEER REVIEW5.19 nM [72]. Chromene-2-thione analogs are also found potent agents while inhibiting12 of 18
TPR with binding affinities of −9.20 to −6.82 kcal/mol [73].

-11.35 kcal/mol
4.78 nM

-8.75 kcal/mol
380 nM

Figure 9. The 3a and 3b binding to the

Figure protein
9. The structure
3a and of Trypanothione
3b binding Reductase
to the protein structure (PDB ID 6T98).
of Trypanothione The top
Reductase panels
(PDB show
ID 6T98).
3a forms H-bonds with Ala The
293 (2.71Å) and Leu
top panels show(3.29
294 Å). The
3a forms 3b forms
H-bonds withH-bonds
Ala 293 with
(2.71 Å)Gly
15 (2.75 Å),
and Leu 294 Gly
(3.29 Å). (3.26
16
The 3bÅ),forms
Ser162
(3.5 and 3.13 Å), Arg (2.23 Å),
287 and Arg
H-bonds with (3.52
290
Gly Å).
15 (Hydrogen
(2.75 16 bonding
Å), Gly (3.26 is shown
Å), Ser 162 by light
(3.5 and 3.13 green
Å), Argcolor(2.23
287 dotted lines).
Å), and Arg290
(3.52 Å). (Hydrogen bonding is shown by light green color dotted lines).
The ligand-protein complexes for 3a, 3b, and native proteins show a comparatively
same potential energy, whereas the 3a complex shows the least fluctuations for RMSD-Cα
(Figure 10). 3b protein complex shows higher RMSD-Cα changes throughout the 100 ns
simulations. Both complexes show RMSD and RMSF changes in the 72–94 amino acids
region. However, the active sites of both ligands don’t overlap, and the primary binding
 Crystals 2022, 12, 44 12 of 17

In a previous study, 600,000 ZINC compounds were screened against leishmanial try-
panothione reductase 20 potential ligands with binding energies of −10.27 to −5.29 kcal/mol
were reported [71]. Fucosterol was found to bind trypanothione reductase with a binding
energy of −8.0 kcal/mol. MM/PBSA energy calculation using YASARA Structure shows a
free energy of −32 and −61 KJ/mol for 3a and 3b complex with PDK (Table 3).
The ligand-protein complexes for 3a, 3b, and native proteins show a comparatively
same potential energy, whereas the 3a complex shows the least fluctuations for RMSD-Cα
(Figure 10). 3b protein complex shows higher RMSD-Cα changes throughout the 100 ns
simulations. Both complexes show RMSD and RMSF changes in the 72–94 amino acids
region. However, the active sites of both ligands don’t overlap, and the primary binding
site residues don’t include these amino acids. This shows that ligand binding might be
affecting this particular region in the enzyme. 3b shows higher fluctuations in RMSF in
the 324–335 amino acid region showing ligand interactions with the part of the enzyme
Crystals 2021, 11, x FOR PEER REVIEW
binding site (Figure 11). This also indicates that ligands 3a and 3b binding induce some
conformational changes in the enzyme.

-1050000

Native
1a
3a
Potential Energy (kJ/mol)

1b
3b

-1100000

-1150000
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100
Time (ns)

3
RMSD Cα (A°)

1
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100

Time (ns)

Figure The
Figure10.10. 100100
The ns MD simulations
ns MD for 3a and
simulations 3awhere
for3b, and 3b,potential
where energy has been
potential shownhas
energy in the
been show
top panel, while RMSD-Cα is shown in the bottom panel. 3a shows comparatively larger
top panel, while RMSD-Cα is shown in the bottom panel. 3a shows comparatively larger fluctuations
in the complex during 20–50 ns of simulations.
tions in the complex during 20–50 ns of simulations.

6
ΔRMSF (Å)

2
 1

0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100
Time (ns)

Figure 10. The 100 ns MD simulations for 3a and 3b, where potential energy has been show
Crystals 2022, 12, 44 top panel, while RMSD-Cα is shown in the bottom panel. 3a shows comparatively
13 of 17 larger
tions in the complex during 20–50 ns of simulations.

ΔRMSF (Å)
4

0
Gl 9
o0

Hi 8
s27

Ph 6
As 45
Me 54

Tr 2
Pr 1

Gl 99

Ph 7
t63
u1

u7
p8
o90

Th 08
r11

Val 26
His 35
Th 144
Se 53
r162

Lys 80
Tyr 89
Ph 98
e207

Le 216
Val 25
Gl 34

As 252
Ph 1
As 270
Val 79
As 288
As 7
Ser 06
Al 15

r360

Th 369
r378

Ph 87
Gl 96

As 423
Val 32
Lys 41
Gl 50

Ph 8
Lys 77
486
Gly 3
Glu 1

As 43
n26

p29

Me 24

342
Th 51

Ar 05
g414

Le 59
u46
Val

t33
Pr

u1

e1
1

r1

y17
1
1
1

u2
2

p2

n3
3

u3
e3

p4
4
4

e4
n

y2

a3

y4

y4
Lys
Val

Gly
n

u
e

Ile
Tyr
Le

Gl

Gl

Gl
Amino acids
15

10
ΔRMSD (Å)

0
Gl l 9
o0

Hi 8
s27
Ph 36
As 45
Me 54
u72

Pr 1

Gl 99

Ph 7
Le 3
u1

p8

r11
o90

Th 108

Val 26
Hi 35
Th 144
Ser 53
162

Lys 80
Tyr 89
Ph 198
Tyr 07
Le 216
Val 25
Gl 234

As 2
Ph 261
As 270
Val 79
As 288
As 7
Ser 06
Ala 15

Ile 0
Th 369
r378

Ph 387
Gl 396

As 3
Val 32
Lys 41
Gl 50

Ph 8
Lys 77
486
t6

Gly33
Va

Gl 71

As 43
n25

p29

Me 24

Gly 2
Th 51
r36

Ar 05
Gl 4
u42

Le 59
u46
Pr

n
e

e1
1

r1

u1
1

e2

u2

p2

n3
3

34

g41

p4
4
4

e4
t3
y1

y2

y4

y4
Val

Lys
u

u
s

e
Tr

Gl

Gl

Amino acids

Figure The
Figure11.11. 3a and
The 3b binding
3a and to the protein
3b binding to the structure
protein of Pyridoxalof
structure Kinase (PDB ID
Pyridoxal 6K92). (PDB
Kinase The ID 6K
top panels show 3a forms H-bonds with Asn 151 (2.69 and 3.44 Å) and Asp231 (3.44 Å). The 3b forms
top panels show 3a forms H-bonds with Asn (2.69 and 3.44Å) and Asp (3.44 Å). The
151 231
H-bonds 187 (3.01 Å), His222 (2.66 and 2.73 Å), and Thr22 (2.87 Å). (Hydrogen bonding is
H-bondswith LysLys
with 187 (3.01 Å), His222 (2.66 and 2.73 Å,) and Thr22 (2.87 Å). (Hydrogen bo
shown by light green color dotted lines).
shown by light green color dotted lines).
3.3. Anti-Leishmanial Activity
Depending upon the IC50 values, anti-leishmanial activities of 3a and 3b were calcu-
lated by MTT assay using the L. amazonensis promastigotes. The intracellular macrophage
susceptibility assay shows 3a and 3b having the IC50 values of 1.164 and 0.085 µg/mL,
respectively (Table 4). The standard drugs show the IC50 values of 0.046 and 3.191 µg/mL.

Table 4. Anti-leishmanial activity of the 3a and 3b ligands.

Ligands IC50 (µg/mL)

3a 1.164 ± 0.123
3b 0.085 ± 0.015
Amphotericin B 0.046 ± 0.101
Miltefosine 3.191 ± 1.10

The ADMET properties analyses show that 3a and 3b possess good physicochemical
characteristics and can be considered as potential drug candidates (Table 5).
Crystals 2022, 12, 44 14 of 17

Table 5. Pharmacokinetics properties of the 3a and 3b.

3a 3b
Molecular weight 294.27 g/mol 407.5 g/mol
Num. H-bond acceptors 5 7
Num. H-bond donors 2 2
Molar Refractivity 85.58 109.33
TPSA 132.77 Å2 178.59 Å2
Log P (lipophilicity) 0.55 0.56
Log S (solubility) (soluble) −3.11 Moderately soluble −4.24
Pharmacokinetics
GI absorption High Low
BBB permeant No No
P-gp substrate No Yes
CYP1A2 inhibitor Yes No
CYP2C19 inhibitor Yes Yes
CYP2C9 inhibitor No Yes
CYP2D6 inhibitor No No
CYP3A4 inhibitor No No
Log Kp (skin permeation) −6.41 cm/s −6.74 cm/s
Druglikeness
Lipinski Yes; 0 violation Yes; 1 violation: NorO > 10
Ghose Yes Yes
Veber Yes No; 1 violation: TPSA > 140
Egan No; 1 violation: TPSA > 131.6 No; 1 violation: TPSA > 131.6
Muegge Yes No; 1 violation: TPSA > 150
Bioavailability Score 0.55 0.55

4. Conclusions
The ligands 3a and 3b, derivatives of 2,3-dihydroquinazolin-4(1H)-one, have been
found to show promising in silico and in vitro anti-leishmanial activities. Both ligands have
shown a strong comparative binding to Pyridoxal Kinase and Trypanothione Reductase
from Leishmania sp. by in silico studies. Some in vivo studies are further required to explore
the potential of the ligands 3a and 3b as non-toxic potent candidates for their use as
leishmanial agents.

Author Contributions: Conceptualization, M.S., M.I.T. and S.X.; methodology, M.S., N.S., F.K. and
S.A.; formal analysis, M.S., S.A., M.F.u.R. and M.J.; investigation, M.S., M.F.u.R., H.E., C.W. and
F.K.; resources, M.F.u.R., M.I.T. and S.X.; writing—original draft preparation, M.S. and M.F.u.R.;
writing—review and editing, F.K., S.X., M.J., C.W. and M.F.u.R.; supervision, M.I.T., N.S. and M.F.u.R.;
funding acquisition, S.X. and F.K.; computational methods including docking and MD simulations,
M.F.u.R. and S.A. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.

References
1. Renslo, A.; McKerrow, J.H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol. 2006, 2, 701–710.
[CrossRef] [PubMed]
2. Akopyants, N.S.K.N.; Secundino, N.; Patrick, R.; Peters, N.; Lawyer, P.; Dobson, D.E.; Beverley, S.M.; Sacks, D.L. Demonstration
of Genetic Exchange During Cyclical Development of Leishmania in the Sand Fly Vector. Science 2009, 324, 265–268. [CrossRef]
[PubMed]
3. Desjeux, P. Leishmaniasis: Public health aspects and control. Clin. Dermatol. 1996, 14, 417–423. [CrossRef]
4. WHO World Health Organization Zoonotic Disease: Emerging Public Health Threats in the Region. Available online: http:
//www.emro.who.int/about-who/rc61/zoonotic-diseases.html (accessed on 18 November 2021).
5. Nascimento, M.M.; Queiroz, J.W.; Barroso, A.W.; Araujo, A.F.; Rego, E.F.; Wilson, M.E.; Pearson, R.D.; Jeronimo, S.M. The
emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans. R. Soc. Trop. Med. Hyg. 2011, 105,
298–300. [CrossRef]
Crystals 2022, 12, 44 15 of 17

6. Aronson, N.; Herwaldt, B.L.; Libman, M.; Pearson, R.; Lopez-Velez, R.; Weina, P.; Carvalho, E.; Ephros, M.; Jeronimo, S.; Magill, A.
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and
the American Society of Tropical Medicine and Hygiene (ASTMH). Am. J. Trop. Med. Hyg. 2017, 96, 24–45. [CrossRef]
7. Leon, L.L.; Carvalho-Paes, L.E.; Grimaldi, J.G. Antigenic differences of Leishmania amazonensis isolate causing diffuse cutaneous
leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1990, 84, 678–680. [CrossRef]
8. Chappuis, F.S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R.W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: What are the needs for
diagnosis, treatment and control? Nat. Rev. Microbiol. 2007, 5, S7–S16. [CrossRef]
9. Pearson, R.D.S. Clinical spectrum of Leishmaniasis. Clin. Infect. Dis. 1996, 22, 1–13. [CrossRef] [PubMed]
10. Modabber, F. Leishmaniasis vaccines: Past, present and future. Int. J. Antimicrob. Agents 2010, 36, S58–S61. [CrossRef]
11. Wise, E.S.; Armstrong, M.; Watson, J.; Lockwood, D.N.J. Monitoring Toxicity Associated with Parenteral Sodium Stibogluconate
in the Day-Case Management of Returned Travellers with New World Cutaneous Leishmaniasi. PLoS Negl. Trop. Dis. 2012, 6,
e1688. [CrossRef]
12. Sundar, S.; More, D.K.; Singh, M.K.; Singh, V.P.; Sharma, S.; Makharia, A.; Kumar, P.C.K.; Murray, H.W. Failure of Pentavalent
Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian Epidemic. Clin. Infect. Dis. 2000, 31, 1104–1107.
[CrossRef]
13. Singh, N.; Kumar, M.; Singh, R.K. Leishmaniasis: Current status of available drugs and new potential drug targets. Asian Pac. J.
Trop. Med. 2012, 5, 485–497. [CrossRef]
14. Bray, P.G.; Barrett, M.; Ward, S.; de Koning, H.P. Pentamidine uptake and resistance in pathogenic protozoa: Past, present and
future. Trends Parasitol. 2003, 19, 232–239. [CrossRef]
15. Torres-Guerrero, E.; Ruiz-Esmenjaud, J.; Arenas, R. Leishmaniasis: A review. F1000Res 2017, 6, 1–15. [CrossRef] [PubMed]
16. Birhan, Y.S.; Bekhit, A.A.; Hymete, A. Synthesis and antileishmanial evaluation of some 2,3-disubstituted-4(3H)-quinazolinone
derivatives. Org. Med. Chem. Lett. 2014, 4, 10. [CrossRef]
17. Bonano, V.I.Y.-Y.; Miguel, D.C.; Jones, S.A.; Dodge, J.A.; Uliana, S.R.B. Discovery of Synthetic Leishmania Inhibitors by Screening
of a 2-Arylbenzothiophene Library. Chem. Biol. Drug Des. 2014, 81, 658–665.
18. Coimbra, E.S.A.; Silva, A.D.; Bispo, M.L.F.; Kaiser, C.R.; De Souza, M.V.N. 7-Chloro-4-quinolinyl hydrazones: A promising and
potent class of antileishmanial compounds. Chem. Biol. Drug. Des. 2013, 81, 658–665. [CrossRef]
19. Gómez-Pérez, V.; Manzano, J.I.; García-Hernández, R.; Castanys, S.; Rosa, J.M.C.; Gamarro, F. 4-Amino Bis-Pyridinium Derivatives
as Novel Antileishmanial Agents. Antimicrob. Agents Chemother. 2014, 58, 4103–4112. [CrossRef]
20. Gellis, A.D.; Lanzada, G.; Hutter, S.; Ollivier, E.; Vanelle, P.; Azas, N. Preparation and antiprotozoal evaluation of promising
β-carboline alkaloids. Biomed. Pharmacother. 2012, 66, 339–347. [CrossRef]
21. Machado, P.A.H.; Carvalho, L.O.; Silveira, M.L.T.; Alves, R.B.; Freitas, R.P.; Coimbra, E.S. Effect of 3-Alkylpyridine marine alkaloid
analogues in Leishmania species related to American cutaneous lLeishmaniasis. Chem. Biol. Drug Des. 2012, 80, 745–751. [CrossRef]
22. Roatt, B.M.; De Brito, R.C.F.; Coura-Vital, W.; de Oliveira Aguiar-Soares, R.D.; Reis, A.B. Recent advances and new strategies on
leishmaniasis treatment. Appl. Microbiol. Biotechnol. 2020, 104, 8965–8977. [CrossRef] [PubMed]
23. Tiuman, T.S.; Santos, A.O.; Ueda-Nakamura, T.; Filho, B.P.D.; Nakamura, C.V. Recent advances in leishmaniasis treatment. Int. J.
Infect. Dis. 2011, 15, e525–e532. [CrossRef] [PubMed]
24. Ramsay, R.R.; Tipton, K.F. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine
Oxidase and Cholinesterase Inhibitory Drugs. Molecules 2017, 22, 1192. [CrossRef]
25. Balbaa, M.; El Ashry, E.S.H. Enzyme Inhibitors as Therapeutic Tools. Biochem. Physiol. Open Access 2012, 1, 13. [CrossRef]
26. Akram, M.S.; Pery, N.; Butler, L.; Shafiq, M.I.; Batool, N.; Rehman, M.F.U.; Grahame-Dunn, L.G.; Yetisen, A.K. Challenges for
biosimilars: Focus on rheumatoid arthritis. Crit. Rev. Biotechnol. 2021, 41, 121–153. [CrossRef]
27. Sarfraz, M.; Tariq, M.I. Synthesis, in silico study and cholinesterases inhibition activity of 2-substituted 2,3-dihydroquinazolin-
4(1H)-one derivatives. Rev. Roum. Chim. 2018, 63, 227–234.
28. Tyagi, R.; Elfawal, M.A.; Wildman, S.A.; Helander, J.; Bulman, C.A.; Sakanari, J.; Rosa, B.A.; Brindley, P.J.; Janetka, J.W.; Aroian,
R.V.; et al. Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics. Sci. Rep. 2019, 9, 9085. [CrossRef]
29. Sultana, N.; Sarfraz, M.; Tanoli, S.T.; Akram, M.S.; Sadiq, A.; Rashid, U.; Tariq, M.I. Synthesis, crystal structure determination,
biological screening and docking studies of N1-substituted derivatives of 2,3-dihydroquinazolin-4(1H)-one as inhibitors of
cholinesterase. Bioorg. Chem. 2017, 72, 256–267. [CrossRef]
30. Sarfraz, M.; Rashid, U.; Sultana, N.; Tariq, M.I. Synthesis, X-Rays Analysis, Docking Study and Cholinesterase Inhibition Activity
of 2, 3-dihydroquinazolin-4 (1H)-one Derivatives. Iran. J. Chem. Chem. Eng. 2019, 38, 213–227.
31. El-Azab, A.S.E.; Eltahir, K.E.H. Design and synthesis of novel 7-aminoquinazoline derivatives: Antitumor and anticonvulsant
activities. Bioorg. Med. Chem. Lett. 2012, 22, 1879–1885. [CrossRef]
32. Saravanan, G.A.; Prakash, C.R. Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-
4-(4-(6,8-dibromo-2-(methyl/ phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives. Bioorg. Med. Chem. Lett. 2012,
22, 3072–3078. [CrossRef] [PubMed]
33. Wang, Z.W.; Wang, M.; Yao, X.; Li, Y.; Tan, J.; Wang, L.; Qiao, W.; Geng, Y.; Liu, Y.; Wang, Q. Design, synthesis and antiviral
activity of novel quinazolinones. Eur. J. Med. Chem. 2012, 53, 275–282. [CrossRef] [PubMed]
34. Abbas, S.E.; Awadallah, F.; Ibrahin, N.A.; Said, E.; Kamel, G. New quinazolinone–pyrimidine hybrids: Synthesis, anti-
inflammatory, and ulcerogenicity studies. Eur. J. Med. Chem. 2012, 53, 141–149. [CrossRef]
Crystals 2022, 12, 44 16 of 17

35. Al-Omary, F.A.; Abou-Zeid, L.A.; Nagi, M.N.; Habib, E.-S.E.; Abdel-Aziz, A.A.-M.; El-Azab, A.S.; Abdel-Hamide, S.G.; Al-Omar,
M.A.; Al-Obaid, A.M.; El-Subbagh, H.I. Non-classical antifolates. Part 2: Synthesis, biological evaluation, and molecular modeling
study of some new 2,6-substituted-quinazolin-4-ones. Bioorg. Med. Chem. 2010, 18, 2849–2863. [CrossRef] [PubMed]
36. Amin, K.; Kamel, M.; Anwar, M.; Khedr, M.; Syam, Y. Synthesis, biological evaluation and molecular docking of novel series of
spiro [(2H,3H) quinazoline-2,10 - cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents. Eur. J. Med. Chem.
2010, 45, 2117–2131. [CrossRef]
37. Mohameda, M.S.K.M.; Kassem, E.M.M.; Abotaleb, N.; AbdEl-moez, S.I.; Ahmeda, M.F. Novel 6,8-dibromo-4(3H)-quinazolinone
derivatives of anti-bacterial and anti-fungal activities. Eur. J. Med. Chem. 2010, 45, 3311–3319. [CrossRef]
38. Gemma, S.C.; Brindisi, M.; Brogi, S.; Kukreja, G.; Kunjir, S.; Gabellieri, E.; Lucantoni, L.; Habluetzel, A.; Taramelli, D.; Basilico, N.;
et al. Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines
and Quinazolines as Potential Antimalarial Agents. J. Med. Chem. 2012, 55, 10387–10404. [CrossRef]
39. Rudolph, J.; O’connor, S.; Coish, P.D.; Wickens, P.L.; Brands, M.; Bierer, D.E.; Bloomquist, B.T.; Bondar, G.; Chen, L.; Chuang, C.Y.;
et al. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J. Med.
Chem. 2007, 50, 5202–5216. [CrossRef]
40. Rhee, H.-K.; Yoo, J.H.; Lee, E.; Kwon, Y.J.; Seo, H.-R.; Lee, Y.-S.; Choo, H.-Y.P. Synthesis and cytotoxicity of 2-phenylquinazolin-
4(3H)-one derivatives. Eur. J. Med. Chem. 2011, 46, 3900–3908. [CrossRef]
41. Radwan, A.A.; Alanazi, F.K. Biological Activity of Quinazolinones, Quinazolinone and Quinazoline Derivatives; IntechOpen: London,
UK, 2020.
42. Faisal, M.; Saeed, A. Chemical Insights into the Synthetic Chemistry of Quinazolines: Recent Advances. Front. Chem. 2021, 8,
594717. [CrossRef]
43. Agarwal, K.; Sharma, V.; Shakya, N.; Gupta, S. Design and synthesis of novel substituted quinazoline derivatives as antileishma-
nial agents. Bioorg. Med. Chem. Lett. 2009, 19, 5474–5477. [CrossRef] [PubMed]
44. Fleita, D.H.; Mohareb, R.M.; Sakka, O.K. Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline
scaffold: A molecular modeling approach. Med. Chem. Res. 2013, 22, 2207–2221. [CrossRef]
45. Tesfahunegn, R.G. Synthesis and Anti-leishmanial Activity Evaluation of Some 2, 3-Disubstituted Quinazoline-4(3H)-Ones
Bearing Quinoline and Pyrazole Moieties. EC Pharma. Sci. 2015, 1, 153–164.
46. Shaterian, H.R.; Ali Reza, O.; Moones, H. Synthesis of 2,3-Dihydroquinazoline-4(1H)-ones. Synth. Commun. 2010, 40, 1231–1242.
[CrossRef]
47. Khattab, S.N.; Haiba, N.S.; Asal, A.M.; Bekhit, A.A.; Guemei, A.A.; Amer, A.; El-Faham, A. Study of antileishmanial activity of
2-aminobenzoyl amino acid hydrazides and their quinazoline derivatives. Bioorg. Med. Chem. Lett. 2017, 27, 918–921. [CrossRef]
48. Asif, M. Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives.
Int. J. Med. Chem. 2014, 2014, 1–27. [CrossRef]
49. Badolato, M.; Aiello, F.; Neamati, N. 2,3-Dihydroquinazolin-4(1H)-one as a privileged scaffold in drug design. RSC Adv. 2018, 8,
20894–20921. [CrossRef]
50. Van Horn, K.S.; Zhu, X.; Pandharkar, T.; Yang, S.; Vesely, B.; Vanaerschot, M.; Dujardin, J.-C.; Rijal, S.; Kyle, D.E.; Wang, M.Z.;
et al. Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines. J. Med. Chem. 2014, 57, 5141–5156.
[CrossRef]
51. Prinsloo, I.F.; Zuma, N.H.; Aucamp, J.; N’Da, D.D. Synthesis and in vitro antileishmanial efficacy of novel quinazolinone
derivatives. Chem. Biol. Drug Des. 2021, 97, 383–398. [CrossRef]
52. Kshirsagar, U.A. Recent developments in the chemistry of quinazolinone alkaloids. Org. Biomol. Chem. 2015, 13, 9336–9352.
[CrossRef]
53. Prashant, S.A.; Gatish, T.P.G. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC
Adv. 2020, 10, 41353–41392.
54. Nayyar, P.; Arpana, R.; Mohd, I. An updated review: Newer quinazoline derivatives under clinical trial. Int. J. Pharm. Biol. Arch.
2011, 2, 1651–1657.
55. Sarfraz, M.; Sultana, N.; Rashid, U.; Akram, M.S.; Sadiq, A.; Tariq, M.I. Synthesis, biological evaluation and docking studies
of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases. Bioorg. Chem. 2017, 70, 237–244. [CrossRef]
[PubMed]
56. Jamil, M.; Sultana, N.; Ashraf, R.; Bashir, M.; Rehman, M.; Kanwal, F.; Ellahi, H.; Lu, C.; Zhang, W.; Tariq, M. Bis (Diamines) Cu
and Zn Complexes of Flurbiprofen as Potential Cholinesterase Inhibitors: In Vitro Studies and Docking Simulations. Crystals
2021, 11, 208. [CrossRef]
57. Tariq, M.I.; Noreen, T.; Tahir, M.N.; Ahmad, S.; Fayyaz-ur-Rehman, M. 2-(2,3-Dimethylphenyl)-1H-isoindole-1,3 (2H)-dione. Acta
Cryst. Sect. E Struct. Rep. Online 2010, 66, 2440. [CrossRef]
58. Lavorato, S.N.; Duarte, M.C.; De Andrade, P.H.R.; Coelho, E.A.F.; Alves, R.J. Synthesis, antileishmanial activity and QSAR studies
of 2-chloro- N -arylacetamides. Braz. J. Pharm. Sci. 2017, 53, 16067. [CrossRef]
59. Krieger, E.; Vriend, G. YASARA View—Molecular graphics for all devices—From smartphones to workstations. Bioinformatics
2014, 30, 2981–2982. [CrossRef]
Crystals 2022, 12, 44 17 of 17

60. Bilal, S.; Hassan, M.M.; Rehman, M.F.; Nasir, M.; Sami, A.J.; Hayat, A. An insect acetylcholinesterase biosensor utilizing WO3/g-
C3N4 nanocomposite modified pencil graphite electrode for phosmet detection in stored grains. Food Chem. 2021, 346, 128894.
[CrossRef]
61. Rehman, M.F.U.; Akhter, S.; Batool, A.I.; Selamoglu, Z.; Sevindik, M.; Eman, R.; Mustaqeem, M.; Akram, M.S.; Kanwal, F.; Lu, C.;
et al. Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World. Antibiotics 2021, 10, 1011.
[CrossRef]
62. Laskowski, R.A.; Swindells, M.B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. Chem. Inf. Model.
2011, 51, 2778–2786. [CrossRef]
63. Fernandez-Poza, S.; Padros, A.; Thompson, R.; Butler, L.; Islam, M.; Mosely, J.; Scrivens, J.H.; Rehman, M.F.; Akram, M.S.
Tailor-made recombinant prokaryotic lectins for characterisation of glycoproteins. Anal. Chim. Acta 2021, 1155, 338352. [CrossRef]
64. Bilal, S.; Sami, A.J.; Hayat, A.; Rehman, M.F.U. Assessment of pesticide induced inhibition of Apis mellifera (honeybee) acetyl-
cholinesterase by means of N-doped carbon dots/BSA nanocomposite modified electrochemical biosensor. Bioelectrochemistry
2021, 144, 107999. [CrossRef] [PubMed]
65. Motulsky, H. Prism 4 Statistics Guide—Statistical Analyses for Laboratory and Clinical Researchers; GraphPad Software Inc.: San Diego,
CA, USA, 2003; pp. 122–126.
66. Fitzpatrick, T.B.; Amrhein, N.; Kappes, B.; Macheroux, P.; Tews, I.; Raschle, T. Two independent routes of de novo vitamin B6
biosynthesis: Not that different after all. Biochem. J. 2007, 407, 1–13. [CrossRef] [PubMed]
67. Coelho, A.C.; Boisvert, S.; Mukherjee, A.; Leprohon, P.; Corbeil, J.; Ouellette, M. Multiple Mutations in Heterogeneous Miltefosine-
Resistant Leishmania major Population as Determined by Whole Genome Sequencing. PLoS Negl. Trop. Dis. 2012, 6, e1512.
[CrossRef] [PubMed]
68. Are, S.; Gatreddi, S.; Jakkula, P.; Qureshi, I.A. Structural attributes and substrate specificity of pyridoxal kinase from Leishmania
donovani. Int. J. Biol. Macromol. 2020, 152, 812–827. [CrossRef]
69. Alfadhel, S. Virtual screening of Leishmanial pyridoxal kinase enzyme inhibitors by repurposed anti-Trypanosomal libraries
reveals two core scaffolds. Latin Am. J. Pharm. 2021, 40, 69–75.
70. Battista, T.; Colotti, G.; Ilari, A.; Fiorillo, A. Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid
Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases. Molecules 2020, 25, 1924. [CrossRef]
71. Matadamas-Martínez, F.; Hernández-Campos, A.; Téllez-Valencia, A.; Vázquez-Raygoza, A.; Comparán-Alarcón, S.; Yépez-Mulia,
L.; Castillo, R. Leishmania mexicana Trypanothione Reductase Inhibitors: Computational and Biological Studies. Molecules 2019, 24,
3216. [CrossRef]
72. Vargas, J.; López, A.; Vargas, A.; Fidalgo, L.; Froeyen, M. In Vitro Evaluation and Molecular Docking Studies of Aryl-Substituted
Imidazoles against Leishmania Amazonensis. Int. J. Trop. Dis. 2021, 4, 50.
73. Verma, R.K.; Prajapati, V.K.; Verma, G.K.; Chakraborty, D.; Sundar, S.; Rai, M.; Dubey, V.K.; Singh, M.S. Molecular Docking and In
Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. ACS Med. Chem. Lett. 2012, 3, 243–247. [CrossRef]